ReviewOncology reports2013

Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review).

Stefan LanghammerPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.